Rhône-Poulenc Biochimie (RPB) produces methylglucamine and directly took part to the infringement as it was represented in the meeting where the original anticompetitive agreement was agreed as well as in all subsequent meetings described above. In its response to the statement of objections, Aventis states, "The infringement has been committed by RPB and by no other affiliated company. Indeed the activities covered by the statement of objections relate exclusively to RPB"(138). They will consequently be the addressees of this Decision.
Recital 209, Decision_act (EU) 2004/104
In forcesince 27 Nov 2002